Agilent Technologies Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:45PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst

Hi. Good morning, everyone. This is Rachel Vatnsdal with the Life Science Tools and Diagnostics team here at JPMorgan. I'm joined by the Agilent management team on stage as these sessions typically are, it's 40 minutes, 20 minutes of presentation and roughly 20 minutes of Q&A afterwards. (Operator Instructions) And with that, I will pass it off to Mike.

Michael R. McMullen - Agilent Technologies, Inc. - CEO, President & Director

Thank you, Rachel. It's a real pleasure to be here today with all of you to share the updated story on Agilent Technologies. As we know, 2023 was quite a challenging year for the industry. But as we think about it from an asset perspective, we think these market challenges we've experienced are transitory across the industry. And as we look forward, we think Agilent is very well positioned for continued long-term growth and shareholder value creation. So why do I say that? The story I'm going to tell you today is Agilent's diversified business with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot